Leerink Partners Sticks to Its Hold Rating for Bluebird Bio (BLUE)

Leerink Partners analyst Mani Foroohar maintained a Hold rating on Bluebird Bio (BLUEResearch Report) on January 28 and set a price target of $11.00. The company’s shares closed last Monday at $7.14, close to its 52-week low of $6.67.

According to, Foroohar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.9% and a 37.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.

Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $12.45.

See today’s best-performing stocks on TipRanks >>

Bluebird Bio’s market cap is currently $500.6M and has a P/E ratio of -0.56.

Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Read More on BLUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed